Encore Dermatology Shares Positive Pivotal Study Results for Impoyz for the Treatment of Plaque Psoriasis

Thursday, January 31, 2019 | Psoriasis


Impoyz Cream (clobetasol propionate) Cream, 0.025% demonstrated efficacy early with 14.2 percent of Impoyz patients achieving treatment success at day 8 versus 1.6 percent in the vehicle group, according to results of a pivitol study that were shared at the 15 th annual Maui Derm Conference. Treatment success was achieved when subjects received a “clear” or “almost clear” assessment, marking at least a 2-grade improvement from their baseline assessment. Efficacy continued during the second week of treatment with 30 percent of subjects in the Impoyz group achieving treatment success compared to nine percent in the vehicle group by day 15.

The primary objective of this trial was to evaluate the efficacy and safety of Impoyz Cream, 0.025% for the treatment of moderate to severe plaque psoriasis in adults 18 years of age and older.

The only adverse reaction reported in the Impoyz group that occurred in at least one percent of subjects treated and was at a higher incidence than the vehicle cream was application site discoloration, two percent versus one percent. Rare adverse events occurring in less than one percent of subjects treated with Impoyz included application site atrophy, telangiectasia and rash.

“The efficacy Impoyz demonstrated in just two weeks is notable considering these were patients with moderate to severe plaque psoriasis at baseline,” says dermatologist Seemal R. Desai, MD, a lead investigator in the study. “Impoyz also provides some comfort based on the low incidence of adverse events reported which is also favorable.”

The study was a Phase 3, randomized, double-blind, vehicle controlled, multicenter trial involving 265 patients with moderate to severe plaque psoriasis. Subjects were randomized (2:1) to treatment with Impoyz Cream or vehicle cream and instructed to apply study product twice daily for 15 consecutive days. Follow-up visits where efficacy was measured were scheduled at day 8, and day 15 of treatment.

“Impoyz Cream offers providers a great alternative to traditional high-potency topical steroids,” says Bob Moccia, President and CEO of Encore Dermatology. “This study helps illustrate Impoyz Cream’s core benefit which is to reduce the likelihood of adverse effects while maintaining favorable efficacy.”

Next Story

Comments

You must be logged in to leave a comment.